The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda
- 61 Downloads
Highly active antiretroviral therapy (HAART) provides dramatic health benefits for HIV-infected individuals in Africa, and widespread implementation of HAART is proceeding rapidly. Little is known about the cost and cost effectiveness of HAART programmes.
To determine the incremental cost effectiveness of a home-based HAART programme in rural Uganda.
A computer-based, deterministic cost-effectiveness model was used to assess a broad range of economic inputs and health outcomes. From the societal perspective, the cost effectiveness of HAART and cotrimoxazole prophylaxis was compared with cotrimoxazole alone, and with the period before either intervention. Data for 24 months were derived from a trial of home-based HAART in 1045 patients in the Tororo District in eastern Uganda. Costs and outcomes were projected out to 15 years. All costs are in year 2004 values. The main outcome measures were HAART programme costs, health benefits accruing to HAART recipients, averted HIV infections in adults and children and the resulting effects on medical care costs.
The first-line HAART regimen consisted of standard doses of stavudine, lamivudine, and either nevirapine or, for patients with active tuberculosis, efavirenz. Second-line therapy consisted of tenofovir, didanosine and lopinavir/ritonavir. For children, first-line HAART consisted of zidovudine, lamivudine and nevirapine syrup; second-line therapy was stavudine, didanosine and lopinavir/ritonavir.
The HAART programme, standardized for 1000 patients, cost an incremental $US1.39 million in its first 2 years. Compared with cotrimoxazole prophylaxis alone, the programme reduced mortality by 87%, and averted 6861 incremental disability-adjusted life-years (DALYs). Benefits were accrued from reduced mortality in HIV-infected adults (67.5% of all benefits), prevention of death in HIV-negative children (20.7%), averted HIV infections in adults (9.1%) and children (1.0%), and improved health status (1.7%). The net programme cost, including the medical cost implications of these health benefits, was $US4.10 million. The net cost per DALY averted was $US597 compared with cotrimoxazole alone. Many HIV interventions have a cost-effectiveness ratio in the range of $US1-150 per DALY averted.
This study suggests that a home-based HAART programme in rural Africa may be more cost effective than most previous estimates for facility-based HAART programmes, but remains less cost effective than many HIV prevention and care interventions, including cotrimoxazole prophylaxis.
KeywordsNevirapine Stavudine Disability Weight Cotrimoxazole Prophylaxis South African Township
The authors contributed to this study in the following ways. Elliot Marseille (first author): concept, design, parameter estimation, literature review, analysis and writing; Dr Marseille had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis; James G. Kahn: concept, design, parameter estimation, analysis and writing; Rebecca Bunnell: concept, design, parameter estimation, analysis and writing; Christian Pitter: concept, design, parameter estimation, analysis and writing; William Epalatai: parameter estimation, analysis and revision; Emmanuel Jawe: parameter estimation, analysis and revision; Willy Were: parameter estimation, analysis and revision; and Jonathan Mermin: concept, design, parameter estimation, analysis and writing.
No ethical approval was required for this research.
Funding was provided by the US Centers for Disease Control and Prevention (CDC) and the Agency for International Development through the President’s Emergency Plan for AIDS Relief. Only CDC staff and consultants on contract to CDC were involved in the study design and implementation, data analysis, and writing of the manuscript. The corresponding author had full access to all data in the study and takes final responsibility for the decision to submit the paper for publication. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC.
The authors have no conflicts of interest that are directly relevant to the content of this study.
- 2.UNAIDS. 2006 report on the global HIV/AIDS epidemic: a UNAIDS 10th anniversary special edition. Geneva: UNAIDS, 2006Google Scholar
- 3.UNAIDS. Resource needs for an expanded response to AIDS in low and middle income countries: “making the money work”. The three ‘ones’ in action [report; discussion paper 9]. Geneva: UNAIDS, 2005 MarGoogle Scholar
- 4.Kombe G, Galaty D, Gadhia R, et al. The human and financial resource requirements for scaling up HIV/AIDS services in Ethiopia [report]. Bethesda (MD): PHRplus and Abt Associates, 2005 FebGoogle Scholar
- 5.Kombe G, Smith O, Nwagbara C. Scaling up antiretroviral treatment in the public sector in Nigeria: a comprehensive analysis of resource requirements [report]. Bethesda (MD): PHRplus and Abt Associates, 2004 FebGoogle Scholar
- 6.Kombe G, Smith O. Application of the AIDSTREATCOST model to estimate the cost of ARV treatment in Zambia and Uganda [PowerPoint presentation]. Bethesda (MD): PHRplus, Abt Associates, and USAID, 2003 Apr 24Google Scholar
- 8.Govender V, McIntyre D, Grimwood A, et al. The costs and perceived quality of care for people living with HIV/AIDS in the Western Cape Province in South Africa [report]. Bethesda (MD): PHR and Abt Associates, 2000 AprGoogle Scholar
- 9.Geffen N, Nattrass N, Raubenheimer C. The cost of HIV prevention and treatment interventions in South Africa [CSRR working paper #28]. Cape Town: Center for Social Science Research, AIDS and Society Research Unit, University of Cape Town, 2003 JanGoogle Scholar
- 10.Cleary S, Jikwana S, Boulle A. Resource requirements for comprehensive HIV and AIDS Care, management and treatment in South Africa: March 2004–March 2009 South African Health Review 2005. Durban: South African Health Systems Trust, 2004Google Scholar
- 13.Cleary S, Boulle A, McIntyre D, et al. Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township. Cape Town: Medecins Sans Frontieres, Health Systems Trust, University of Capetown, 2004 MarchGoogle Scholar
- 15.Uganda Bureau of Statistics, Macro International. Uganda demographic and health survey 2006. Calverton (MD), 2001: 500Google Scholar
- 16.UNAIDS. 2008 report on the global HIV/AIDS epidemic. Geneva: UNAIDS, 2008: 236Google Scholar
- 17.World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults in resource-limited settings: recommendations for a public health approach. Geneva: WHO, 2006Google Scholar
- 20.Mathers CD, Bernard C, Iburg KM, et al. Global burden of disease in 2002: data sources, methods and results (revised) [Global Programme on Evidence for Health Policy discussion paper no. 54]. Geneva: WHO, 2004Google Scholar
- 21.Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. 2nd ed. New York: Oxford University Press, 2006Google Scholar
- 22.Expenditure reports. Entebbe: Centers for Disease Control and Prevention, Global AIDS Program, 2004. (Data on file)Google Scholar
- 23.Medecins Sans Frontières. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. 10th ed. Geneva: Medecins Sans Frontières, 2007Google Scholar
- 24.Time and motion data. Entebbe: Centers for Disease Control and Prevention, Global AIDS Program, 2005 Aug. (Data on file)Google Scholar
- 26.HBAC Program weekly home-visit records. Entebbe: Centers for Disease Control and Prevention, Global AIDS Program, 2004. (Data on file)Google Scholar
- 30.Mermin J. Mortality rates for HIV-negative children (<10yrs). 2006 Jan 25 (Data on file)Google Scholar
- 37.Palombi L, Germano P, Liotta G, et al. DREAM program: 6-month follow-up of the prevention of mother-to-child transmission service [abstract no. 723]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)Google Scholar
- 38.Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications, 1997Google Scholar
- 39.Medecins Sans Frontières. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. 10th ed. Geneva: Médecins Sans Frontieres, 2007 JulGoogle Scholar
- 40.World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Geneva: WHO, 2007Google Scholar
- 41.Médecins Sans Frontières. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. 8th ed. Geneva: Médecins Sans Frontières, 2005Google Scholar
- 42.McFadyen J. International drug price indicator guide. Cambridge: Management Sciences for Health, 2005Google Scholar
- 43.Palombi L, Germano P, Liotta G, et al. The DREAM cohort: antiretroviral treatment for PMTCT. HAART in pregnancy: safety, effectiveness, and protection from viral resistance. Results from the DREAM cohort [abstract no. 67]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA)Google Scholar
- 46.Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362(9387): 859–68PubMedCrossRefGoogle Scholar
- 51.New agreements to lower prices of HIV/AIDS rapid tests and second-line drug [press release; online]. Available from URL: http://www.clintonfoundation.org/011206-nr-cf-hs-ai-isr-ind-chn-zaf-bra-pr-new-agreements-to-lower-prices-of-hiv-aids-rapid-tests-and-second-line-drugs.htm [Accessed 2006 May 19]
- 54.Page-Shafer KA, McFarland W, Kohn R, et al. Increases in unsafe sex and rectal gonorrhea among men who have sex with men: San Francisco, California, 1994–1997. MMWR Morb Mortal Wkly Rep 1999; 48(3): 45–8Google Scholar
- 57.Over M, Heywood P, Gold J, et al. HIV/AIDS treatment and prevention in India: modeling the costs and consequences. Washington, DC: The World Bank, 2004Google Scholar
- 59.Over M, Heywood P, Gold J, et al. HIV prevention and treatment in India: modeling the costs and consequences. Washington, DC: The World Bank, 2004Google Scholar